Price movement over the last 24 hours
ARK Genomic Revolution ETF vs iShares Core MSCI EAFE ETF — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while iShares Core MSCI EAFE ETF trades at $96.73. Which is the better fit depends on your goals.
| ARKG | IEFA | |
|---|---|---|
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $43.57 | $98.56 |
52-Week Low | $23.09 | $81.70 |
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
IEFA trades at $97.22, up 0.51% with a bullish technical signal from moving averages. The ETF provides developed international equity exposure excluding North America, offering diversification from US market concentration risks. Recent news highlights its competitive 0.07% expense ratio and 3.30% dividend yield compared to peers. Technical indicators show neutral oscillators but strong bullish momentum from moving averages.
The outlook remains positive given international diversification benefits and potential Fed rate cut catalysts. Key risks include currency fluctuations and developed market central bank policy shifts. With strong institutional interest and favorable analyst comparisons to broader international ETFs, IEFA presents a cost-effective developed markets exposure opportunity for US investors seeking geographic diversification.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →